Buy Veradermics stock | $MANE Share Price

13:30

15:10

16:45

18:25

20:00

About Veradermics

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

Ticker

$MANE

Sector

Health

Primary listing

NYSE

Employees

Headquarters

New Haven, United States

Website

www.veradermics.com

Veradermics Metrics

BasicAdvanced

$2.3B

-$83.10

What the Analysts think about Veradermics

Analyst ratings (Buy, Hold, Sell) for Veradermics stock.

Bulls say / Bears say

Veradermics shares jumped 122% in their NYSE debut, closing at $37.75 compared to the $17 IPO price in an offering that was oversubscribed by double digits, showing strong investor demand and market confidence. (Bloomberg)

The company raised about $294.8 million in gross proceeds via its upsized IPO, including the full exercise of the underwriters’ option, giving it the resources to fund multiple Phase 3 trials and operations. (Reuters)

Veradermics completed enrollment in its second pivotal Phase 3 trial of VDPHL01 for male pattern hair loss, fully enrolling all male studies (~1,000 participants) and reducing the risk regarding this key clinical milestone ahead of topline data in 1H 2026. (Investing.com)

The company’s net loss grew to $48 million for the nine months ended September 30, 2025, up from $21 million the previous year, highlighting significant cash burn without revenue to cover expenses. (Reuters)

Despite raising substantial capital, the IPO announcement did not provide details on any pipeline candidates aside from VDPHL01, leaving the company exposed to pipeline concentration risk focused on a single program. (Reuters)

With shares trading around $38.48, just 4% under its 52-week high, Veradermics’ valuation is over $1 billion even though it has no approved products and still faces pivotal Phase 3 results, which raises significant downside risk. (Investing.com)

Data summarised monthly by Lightyear AI. Last updated on 15 Mar 2026.

Veradermics Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Veradermics Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MANE

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Veradermics stock?

Veradermics (MANE) has a market cap of $2.3B as of March 24, 2026.

What is the P/E ratio for Veradermics stock?

The price to earnings (P/E) ratio for Veradermics (MANE) stock is 0 as of March 24, 2026.

Does Veradermics stock pay dividends?

No, Veradermics (MANE) stock does not pay dividends to its shareholders as of March 24, 2026.

When is the next Veradermics dividend payment date?

Veradermics (MANE) stock does not pay dividends to its shareholders.

What is the beta indicator for Veradermics?

Veradermics (MANE) does not currently have a Beta indicator.

Bulls say / Bears say

Data summarised monthly by Lightyear AI. Last updated on 15 Mar 2026.

About Veradermics

Ticker

Primary listing

Employees

Veradermics Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Veradermics

Analyst Ratings

Bulls say / Bears say

Veradermics Financial Performance

Income Statement

Veradermics Earnings Performance

Earnings per share (EPS)

Veradermics News

Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting

Veradermics to Participate in Upcoming March Investor Conferences

Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill

Buy $MANE

Upcoming events

No upcoming events

What’s the current market cap for Veradermics stock?

What is the P/E ratio for Veradermics stock?

Does Veradermics stock pay dividends?

When is the next Veradermics dividend payment date?

What is the beta indicator for Veradermics?

Lightyear

Legal

Work with us

Bulls say / Bears say

Veradermics/$MANE

About Veradermics

Ticker

Primary listing

Employees

Veradermics Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Veradermics

Analyst Ratings

Bulls say / Bears say

Veradermics Financial Performance

Income Statement

Veradermics Earnings Performance

Earnings per share (EPS)

Veradermics News

Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting

Veradermics to Participate in Upcoming March Investor Conferences

Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill

Buy $MANE

Upcoming events

No upcoming events

What’s the current market cap for Veradermics stock?

What is the P/E ratio for Veradermics stock?

Does Veradermics stock pay dividends?

When is the next Veradermics dividend payment date?

What is the beta indicator for Veradermics?

Bulls say / Bears say